Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
Nasrin Saleh JouneghaniJohn PhillipConstantin A DasanuPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
The mechanism by which cemiplimab caused insulin-dependent diabetes mellitus is most likely due to lack of endogenous insulin production in the setting of immune-mediated loss of pancreatic beta-cells. Patients may benefit from fasting blood glucose monitoring and early immune checkpoint inhibitor discontinuation where elevated serum glucose is detected.
Keyphrases
- type diabetes
- glycemic control
- blood glucose
- end stage renal disease
- induced apoptosis
- chronic kidney disease
- newly diagnosed
- ejection fraction
- insulin resistance
- cardiovascular disease
- prognostic factors
- multiple sclerosis
- signaling pathway
- oxidative stress
- skeletal muscle
- adipose tissue
- cell death
- blood pressure
- metabolic syndrome